Indian Biotechs Seek To Outsource Drug Marketing To MNCs
This article was originally published in PharmAsia News
In somewhat of a trend reversal, some Indian biotechs are outsourcing their own drug projects as the drug-making business tightens. Avesthagen and Biocon have their own pipeline of drugs in development, but are discussing possible partnerships with multinational drug makers. Avesthagen has a nutritional molecule in clinical trials and seeks a MNC willing to market the drug while Avesthagen focuses on four other molecules in the pre-clinical stage. Biocon is in a similar situation with an insulin molecule just entering Phase III trials. (Click here for more
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.